Postmenopausal Endometriosis — When Disease Persists

Endometriosis is usually considered a disease of reproductive-age women, but disease activity can persist or recur after menopause. This page covers when postmenopausal endometriosis develops, the diagnostic challenges, and management considerations including hormone therapy decisions.

1. Why disease may persist

Most endometriosis activity declines after menopause due to oestrogen withdrawal. But residual lesions can persist. Peripheral aromatisation in adipose tissue produces local oestrogen even after ovarian failure. Endometriotic lesions express aromatase locally, generating their own oestrogen. Hormone replacement therapy can reactivate dormant disease. Approximately 2–4 percent of endometriosis cases present after menopause.

2. Clinical presentation

Persistent pelvic pain (may be similar to reproductive-age symptoms). Ovarian masses on routine imaging — must be evaluated for both endometriosis and malignancy. Bowel symptoms — endometriosis can mimic colorectal pathology. Urinary symptoms. Postmenopausal bleeding — though not typical of endometriosis, requires full evaluation. Incidental finding on imaging for other reasons.

3. The malignancy question

Critical consideration — endometriosis-associated ovarian cancer (clear cell and endometrioid types) is a recognised long-term risk. Postmenopausal ovarian masses with endometrioma features need careful evaluation. MRI characterisation. CA-125 with HE4 (Risk of Ovarian Malignancy Algorithm). Surgical assessment if features concerning. Cannot assume an ovarian mass in postmenopausal endometriosis patient is benign.

4. Diagnosis

Pelvic ultrasound — IDEA protocol still applies. MRI essential for malignancy evaluation. CA-125 and HE4. Endometrial biopsy if abnormal bleeding. Surgical biopsy if suspicious features. Lower threshold for surgical intervention compared to premenopausal disease due to malignancy concerns.

5. HRT decisions

HRT can reactivate dormant endometriosis. Risk depends on disease severity, residual lesions, and HRT type. Combined estrogen-progestin preferred over estrogen-only. Continuous combined HRT may reduce reactivation risk vs sequential. Patients should be counselled about symptoms suggesting reactivation. Surveillance during HRT use.

6. Symptom management

Hormone-suppression options limited (already postmenopausal). Aromatase inhibitors (letrozole, anastrozole) — block peripheral oestrogen production and locally in lesions. Surgical management of symptomatic disease. Pain medication for refractory symptoms. Pelvic floor physiotherapy still valuable.

7. Surgical considerations

Lower threshold for surgery due to malignancy concerns. Definitive hysterectomy with bilateral salpingo-oophorectomy may be appropriate. Histological assessment of all removed tissue. Bowel/bladder/ureteric involvement managed multidisciplinary. Recovery considerations for older patients.

8. Long-term monitoring

Annual pelvic examination and ultrasound. CA-125 surveillance in selected cases. Pap and HPV screening continues per general guidelines. Patient education about reactivation symptoms during HRT. Open access for symptom changes.

Frequently Asked Questions

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.